The company announced that its Phase III FENhance 1 and 2 studies both met their primary endpoints
The start of our Phase 3 trial for an H5 influenza vaccine marks a significant milestone
The Phase III METEOROID study met its primary endpoint, with ENSPRYNG cutting the risk of a first relapse by 68% compared to placebo in adults and adolescents
IgAN is a rare, progressive kidney disease driven by abnormal IgA immune complexes that deposit in the kidneys
The newly formed SAB will provide strategic direction across research, clinical development, and regulatory pathways
By prioritising absolute compliance, leveraging the power of digital tools, and aligning with government policies, the sector is locking in its future leadership
OneSource is the contract development and manufacturing organization (CDMO) partner for this product
Shift from approvals to digital intimation via NSWS portal aims to cut timelines and boost innovation in early-stage drug development
AI-enabled learning platform to enhance clinical quality, patient outcomes, and staff engagement across Eastern India network
The newly formed team is led by Tomabu Adjobimey, an immunologist known for his work in host-pathogen interactions and immune modulation
Subscribe To Our Newsletter & Stay Updated
